시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 아스페르길루스증(Aspergillosis) 치료 시장 보고서(2025년)
Aspergillosis Treatment Global Market Report 2025
상품코드 : 1824591
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,666,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,635,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,605,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

아스페르길루스증(Aspergillosis) 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년 연평균 복합 성장률(CAGR)은 6.4%를 나타내 42억 3,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 이식의료에 대한 수요, 혈액 악성종양의 유행, 연구개발에 대한 투자 증가, 공중위생의 대처에 기인하고 있습니다. 예측 기간의 주요 동향에는 항진균제 내성, 표적 치료, 치료제 모니터링, 의약품 개발 등이 있습니다.

향후 5년간의 예측 성장률 6.4%는 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 인도와 스페인에서 조달하는 보리코나졸과 암포테리신 B 제제의 비용을 증가시켜 미국 항진균 요법을 억제하고, 면역결핍 환자의 치료를 지연시키고, 감염 부문의 지출을 증가시킬 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

진균 감염의 유병률 증가는 아스페르길루스증(Aspergillosis) 치료 시장 확대를 촉진할 것으로 예측됩니다. 곰팡이 감염(진균증)은 곰팡이로 인한 질병으로 인간과 동물 모두에 영향을 줄 수 있습니다. 곰팡이 감염의 일종인 아스페르길루스증은 호흡기 시스템, 폐, 뇌, 신장 및 기타 기관과 같은 신체의 다양한 부위에 영향을 줄 수 있습니다. 항진균제 보리코나졸과 같은 아스페르길루스증의 치료는 감염을 조절하고, 증상을 완화하고, 합병증을 예방하며, 전신 건강을 증진시키는 것을 목표로 합니다. 예를 들어, 2023년 9월 영국 건강 안보국은 잉글랜드에서 혈류 효모 감염 증가를 보고했고, 사례 수는 2021년 인구 10만 명당 3.8명에서 2022년에는 4명으로 증가했습니다. 그 결과, 진균 감염의 이환율의 상승이 아스페르길루스증(Aspergillosis) 치료 시장 성장을 가속하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Aspergillosis treatment refers to addressing a fungal infection caused by the aspergillus species, with the specific approach depending on the severity and type of the disease. Aspergillosis can pose a serious and potentially life-threatening threat, particularly to individuals with compromised immune systems.

The primary categories of aspergillosis treatment encompass allergic aspergillosis, chronic aspergillosis, invasive aspergillosis, and other variants. Allergic aspergillosis, also recognized as allergic bronchopulmonary aspergillosis (ABPA), denotes a specific allergic response to the Aspergillus fungus, most frequently associated with Aspergillus fumigatus. Various classes of drugs are utilized, including corticosteroids, antifungal medications, and others. These treatments can be administered through oral, injectable, and alternative routes, and are distributed through a range of channels such as hospital pharmacies, retail pharmacies, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The aspergillosis treatment market research report is one of a series of new reports from The Business Research Company that provides aspergillosis treatment market statistics, including aspergillosis treatment industry global market size, regional shares, competitors with an aspergillosis treatment market share, detailed aspergillosis treatment market segments, market trends and opportunities and any further data you may need to thrive in the aspergillosis treatment industry. This aspergillosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aspergillosis treatment market size has grown strongly in recent years. It will grow from $3.14 billion in 2024 to $3.3 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to diagnostic advancements, demand for antifungal medications, increased incidence, invasive procedures.

The aspergillosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.23 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to demand for transplant medicine, prevalence of hematologic malignancies, increasing investments in research and development, public health initiatives. Major trends in the forecast period include antifungal resistance, targeted therapies, therapeutic drug monitoring, drug development.

The forecast of 6.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. antifungal therapy by increasing the cost of voriconazole and amphotericin B formulations sourced from India and Spain, thereby delaying treatment for immunocompromised patients and elevating infectious disease department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of fungal infections is anticipated to drive the expansion of the aspergillosis treatment market. Fungal infections, or mycoses, are diseases caused by fungi that can affect both humans and animals. Aspergillosis, a specific type of fungal infection, can impact various parts of the body, including the respiratory system, lungs, brain, kidneys, and other organs. Treatments for aspergillosis, such as the antifungal medication voriconazole, aim to control infection, relieve symptoms, prevent complications, and enhance overall health. For example, in September 2023, the UK Health Security Agency reported an increase in bloodstream yeast infections in England, with cases rising from 3.8 per 100,000 people in 2021 to 4.0 in 2022. Consequently, the rising incidence of fungal infections is fueling growth in the aspergillosis treatment market.

Increasing healthcare expenditures are expected to drive growth in the aspergillosis treatment market. Healthcare expenditures encompass all costs related to health services, family planning, nutrition programs, and emergency health assistance. An increase in these expenditures supports the advancement of more effective treatments and medical technologies for managing aspergillosis. For example, in May 2023, the Office for National Statistics reported that healthcare spending in the UK reached approximately $362.08 billion (£292 billion), marking a 5.6% nominal increase. Additionally, spending on long-term health and social care rose by 2.8% in real terms in 2022. As a result, rising healthcare spending is bolstering the aspergillosis treatment market's growth.

Prominent companies in the aspergillosis treatment sector are dedicated to introducing cutting-edge drugs and solutions to maintain their competitive edge. These breakthroughs in drug development broaden the spectrum of treatment options available for aspergillosis. An example of this progress is the introduction of posaconazole oral suspension, which offers more precise and efficient treatment choices for patients. Notably, in April 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched Posaconazole oral suspension in the US for treating aspergillosis. This medication is particularly relevant for patients with severely compromised immune systems, like hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), who are at high risk of developing invasive aspergillus and candida infections. Furthermore, posaconazole oral suspension is recommended for oropharyngeal candidiasis (OPC), particularly when it proves refractory to itraconazole and fluconazole.

In May 2022, F2G Ltd., a pharmaceutical company based in England, entered into a partnership with Shionogi & Co., Ltd. to advance the development and commercialization of olorofim, an innovative antifungal treatment for invasive fungal infections, including invasive aspergillosis, across Europe and Asia. Shionogi & Co., Ltd., headquartered in Japan, specializes in developing treatments for invasive aspergillosis and other serious fungal infections.

Major companies operating in the aspergillosis treatment market are Basilea Pharmaceutica Ltd., Pfizer Inc., Johnson and Johnson, AbbVie Inc., Bayer AG, Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries, Astellas Pharma Inc., Regeneron Pharmaceuticals, Mylan N.V., Sun Pharmaceutical Industries, Jazz Pharmaceuticals, Dr. Reddy's Laboratories, Cipla Ltd., Bruker Corporation, Hikma Pharmaceuticals PLC.

North America was the largest region in the aspergillosis treatment market in 2024. The regions covered in aspergillosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the aspergillosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The aspergillosis treatment market consists of sales of immunotherapy drugs, echinocandin and azole antifungals. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Aspergillosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on aspergillosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for aspergillosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The aspergillosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Aspergillosis Treatment Market Characteristics

3. Aspergillosis Treatment Market Trends And Strategies

4. Aspergillosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Aspergillosis Treatment Growth Analysis And Strategic Analysis Framework

6. Aspergillosis Treatment Market Segmentation

7. Aspergillosis Treatment Market Regional And Country Analysis

8. Asia-Pacific Aspergillosis Treatment Market

9. China Aspergillosis Treatment Market

10. India Aspergillosis Treatment Market

11. Japan Aspergillosis Treatment Market

12. Australia Aspergillosis Treatment Market

13. Indonesia Aspergillosis Treatment Market

14. South Korea Aspergillosis Treatment Market

15. Western Europe Aspergillosis Treatment Market

16. UK Aspergillosis Treatment Market

17. Germany Aspergillosis Treatment Market

18. France Aspergillosis Treatment Market

19. Italy Aspergillosis Treatment Market

20. Spain Aspergillosis Treatment Market

21. Eastern Europe Aspergillosis Treatment Market

22. Russia Aspergillosis Treatment Market

23. North America Aspergillosis Treatment Market

24. USA Aspergillosis Treatment Market

25. Canada Aspergillosis Treatment Market

26. South America Aspergillosis Treatment Market

27. Brazil Aspergillosis Treatment Market

28. Middle East Aspergillosis Treatment Market

29. Africa Aspergillosis Treatment Market

30. Aspergillosis Treatment Market Competitive Landscape And Company Profiles

31. Aspergillosis Treatment Market Other Major And Innovative Companies

32. Global Aspergillosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Aspergillosis Treatment Market

34. Recent Developments In The Aspergillosis Treatment Market

35. Aspergillosis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기